Market Overview

Benzinga's Top Downgrades

Benzinga's Top Downgrades

Analysts at Piper Jaffray downgraded MAKO Surgical (NASDAQ: MAKO) from “overweight” to “neutral.” The target price for MAKO Surgical has been raised from $26 to $30. MAKO Surgical's shares closed at $29.70 yesterday.

Analysts at Barclays downgraded ARIAD Pharmaceuticals (NASDAQ: ARIA) from “overweight” to “underweight.” The target price for ARIAD Pharmaceuticals has been lowered from $25 to $4. ARIAD Pharmaceuticals' shares closed at $5.83 yesterday.

Nomura downgraded Maxim Integrated Products (NASDAQ: MXIM) from “buy” to “neutral.” The target price for Maxim Integrated Products is set to $28. Maxim Integrated's shares closed at $29.22 yesterday.

Analysts at Ascendiant Capital downgraded Leapfrog Enterprises (NYSE: LF) from “buy” to “neutral.” The target price for Leapfrog Enterprises has been lowered from $12 to $8. Leapfrog's shares closed at $9.15 yesterday.

Latest Ratings for MAKO

Oct 2013DowngradesOverweightNeutral
Sep 2013DowngradesBuyNeutral
Sep 2013DowngradesOutperformMarket Perform

View More Analyst Ratings for MAKO
View the Latest Analyst Ratings

Posted-In: Top DowngradesDowngrades Analyst Ratings


Related Articles (ARIA + LF)

View Comments and Join the Discussion!

Latest Ratings

TOLGoldman SachsInitiates Coverage On42.0
KBHGoldman SachsInitiates Coverage On36.0
YEXTSunTrust Robinson HumphreyMaintains28.0
LHCGSunTrust Robinson HumphreyMaintains160.0
DLRSunTrust Robinson HumphreyMaintains140.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Conflicting PC Numbers Still Show a Market in Decline

The One Emerging Market ETF To Own (ECON, EEM)